Inivata
2014
FOUNDED
PRIVATE
STATUS
Series B
LATEST DEAL TYPE
$52.4M
LATEST DEAL AMOUNT
7
INVESTORS
Description
Provider of a cancer genomics monitoring platform intended to improve personalized healthcare in oncology. The company's platform unlocks essential genomic information from a simple blood test, focuses on harnessing the potential of circulating tumor DNA (ctDNA) analysis, enabling doctors to improve cancer testing and treatment.
Website
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Laboratory Services (Healthcare)
Other Industries
Biotechnology
Primary Office
- The Portway Building
- Granta Park
- Cambridge CB21 6GS
- England, United Kingdom
+44 01223 000000
Request full access to PitchBook
You’re viewing a free company profile from the PitchBook Platform. To explore Inivata’s full profile, request a free trial.
Inivata Valuation and Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Later Stage VC (Series B) | 29-Mar-2019 | $52.4M | 00000 | 000.00 | Completed | Generating Revenue |
| 2. Early Stage VC (Series A) | 26-Jan-2016 | 000.00 | 000.00 | 0000 | Completed | Generating Revenue |
| 1. Early Stage VC | 23-Sep-2014 | $6.55M | $6.55M | 000 | Completed | Generating Revenue |
Inivata Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | 00,000,000 | 00.000000 | 00.0 | 00.0 | 00 | 00.0 | 00.000 | |
| Series B | 0,000,000 | 00.000000 | 00.00 | 00.00 | 00 | 00.00 | 00.000 | |
| Deferred | 0,000,000 | 00.000000 | 00.00 | 00.00 | 00 | 00.00 | 0.000 | |
| Series A | 16,591,575 | $0.000013 | 7% | $2.5 | $2.5 | 1x | $2.5 | 37.04% |
| Preference | 4,000,000 | $0.000013 | 5% | $1.32 | $1.32 | 1x | $1.32 | 8.93% |
Inivata Competitors (52)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| GeneCast Biotechnology | Venture Capital-Backed | Beijing, China | 000.00 | 00000000000 | 000.00 | |
| 00000000 | Private Equity-Backed | Seattle, WA | 0000 | 000000000 | 0000 | |
| 0000000000 0000000 | Private Equity-Backed | Vancouver, Canada | 0000000000 | |||
| 0000000000 | Venture Capital-Backed | Jerusalem, Israel | 00 | 000.00 | 000000&0 | |
| 0000000000 0000000 | Corporate Backed or Acquired | Cambridge, MA | 000 | 00000 | 00000000000 |
Inivata Investors (7)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Board Seat |
Contact Info |
|---|---|---|---|---|---|---|
| RT Ventures | Venture Capital | Minority | 000 0000 | 000000 0 | ||
| IP Group | Venture Capital | Minority | 000 0000 | 000000 0 | ||
| Woodford Investment Management | Asset Manager | Minority | 000 0000 | 000000 0 | ||
| Cambridge Innovation Capital | Venture Capital | Minority | 000 0000 | 000000 0 | ||
| Cancer Research UK | Venture Capital | Minority | 000 0000 | 000000 0 |
Inivata Executive Team (16)
5 Former Executives
You’re viewing 5 of 16 executives. Get the full list »Inivata Board Members (10)
| Name | Representing | Role | Since | Contact Info |
|---|---|---|---|---|
| Jeanne Bolger MD | Johnson & Johnson Innovation - JJDC | Board Member | 000 0000 | |
| Jeffrey Buchalter | Inivata | Non-Executive Chairman | 000 0000 | |
| Keith Blundy Ph.D | Cancer Research UK | Board Member | 000 0000 | |
| Nitzan Rosenfeld Ph.D | Inivata | Chief Scientific Officer, Co-Founder & Board Member | 000 0000 | |
| Patrick Terry | Self | Board Member | 000 0000 |
3 Former Board Members
You’re viewing 5 of 10 board members. Get the full list »